$XBI $87.98 | -0.5%
Covid Updates
$MRNA -2.1% Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate source
Pipeline Updates
$ALLO -1.3% Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma source
$TGTX -1.3% TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting source
$TCON +18.2% TRACON Pharmaceuticals Announces FDA Approval Of Amended ENVASARC Protocol source
$COCP -1.1% Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344 source
$TLSA +30.4% Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody source
$PASG -0.2% PASSAGE BIO DOSES FIRST PATIENT IN GLOBAL CLINICAL TRIAL FOR INFANTILE KRABBE DISEASE, A RARE FATAL PEDIATRIC CONDITION source
$IMGN -2.5% ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at the Society of Gynecologic Oncology Annual Meeting source
Business Updates
$ERAS -2.2% ERASCA ANNOUNCES CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH ELI LILLY AND COMPANY TO EVALUATE ERAS-007 AND CETUXIMAB COMBINATION source
Posted by JM
Comments